

Stephanie Daignault

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12099406/publications.pdf>

Version: 2024-02-01

34
papers

2,988
citations

331670

21
h-index

454955

30
g-index

34
all docs

34
docs citations

34
times ranked

3879
citing authors

#	ARTICLE	IF	CITATIONS
1	Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect. Journal of the National Cancer Institute, 2006, 98, 1331-1334.	6.3	1,032
2	Partial Nephrectomy for Small Renal Masses: An Emerging Quality of Care Concern?. Journal of Urology, 2006, 175, 853-858.	0.4	312
3	Five-year survival after surgical treatment for kidney cancer. Cancer, 2007, 109, 1763-1768.	4.1	247
4	Cystectomy Delay More Than 3 Months From Initial Bladder Cancer Diagnosis Results in Decreased Disease Specific and Overall Survival. Journal of Urology, 2006, 175, 1262-1267.	0.4	168
5	Volume-Based Referral for Cancer Surgery: Informing the Debate. Journal of Clinical Oncology, 2007, 25, 91-96.	1.6	129
6	Patterns of Hematuria Referral to Urologists: Does a Gender Disparity Exist?. Urology, 2008, 72, 498-502.	1.0	126
7	Inhibition of DNA Methyltransferase Activity Prevents Tumorigenesis in a Mouse Model of Prostate Cancer. Cancer Research, 2006, 66, 385-392.	0.9	125
8	Elevated E2F1 Inhibits Transcription of the Androgen Receptor in Metastatic Hormone-Resistant Prostate Cancer. Cancer Research, 2006, 66, 11897-11906.	0.9	100
9	Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. Journal of Urology, 2015, 194, 790-798.	0.4	85
10	Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Investigational New Drugs, 2012, 30, 749-757.	2.6	72
11	Worsening Central Sarcopenia and Increasing Intra-abdominal Fat Correlate with Decreased Survival in Patients with Adrenocortical Carcinoma. World Journal of Surgery, 2012, 36, 1509-1516.	1.6	70
12	Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Investigational New Drugs, 2012, 30, 249-257.	2.6	66
13	Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiotherapy and Oncology, 2015, 116, 179-184.	0.6	61
14	ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms. Cancer Research, 2015, 75, 5155-5166.	0.9	59
15	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Investigational New Drugs, 2011, 29, 1432-1440.	2.6	49
16	Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. Radiotherapy and Oncology, 2014, 110, 291-297.	0.6	39
17	Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. Prostate, 2017, 77, 479-488.	2.3	39
18	Multi-institutional Prospective Evaluation of Bowel Quality of Life After Prostate External Beam Radiation Therapy Identifies Patient and Treatment Factors Associated With Patient-Reported Outcomes: The PROSTQA Experience. International Journal of Radiation Oncology Biology Physics, 2013, 86, 546-553.	0.8	36

#	ARTICLE	IF	CITATIONS
19	Comparison of joint modeling and landmarking for dynamic prediction under an illness-death model. <i>Biometrical Journal</i> , 2017, 59, 1277-1300.	1.0	34
20	A quantitative tool to assess degree of sarcopenia objectively in patients with hypercortisolism. <i>Surgery</i> , 2011, 150, 1178-1185.	1.9	32
21	Hospital Characteristics and Use of Innovative Surgical Therapies Among Patients With Kidney Cancer. <i>Medical Care</i> , 2008, 46, 372-379.	2.4	30
22	Categorizing renal oncocytic neoplasms on core needle biopsy: a morphologic and immunophenotypic study of 144 cases with clinical follow-up. <i>Human Pathology</i> , 2016, 55, 1-10.	2.0	21
23	The E2F1/DNMT1 axis is associated with the development of AR negative castration resistant prostate cancer. <i>Prostate</i> , 2013, 73, 1776-1785.	2.3	17
24	Understanding differences between high and low volume hospitals for radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 260-265.	1.6	13
25	Response: Re: Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect. <i>Journal of the National Cancer Institute</i> , 2007, 99, 570-571.	6.3	8
26	Automated Area Calculation of Histopathologic Features Using SIVQ. <i>Analytical Cellular Pathology</i> , 2011, 34, 265-275.	1.4	8
27	Phase II clinical trial of intravesical bacillus Calmette-Guerin (BCG) followed by sunitinib for the treatment of high-risk nonmuscle-invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 293-293.	1.6	6
28	Concordance of ETS fusion status of matched metastatic castration-resistant prostate cancer and primary prostate cancer: Data from NCI 9012, a randomized ETS fusion-stratified phase II trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5019-5019.	1.6	2
29	Cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219): Evaluation of bone metastasis microenvironment.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16015-e16015.	1.6	1
30	Comprehensive molecular profiling of pretreatment metastatic castration resistant prostate cancer (CRPC): Secondary data from NCI 9012, a randomized ETS fusion-stratified phase II trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16038-e16038.	1.6	1
31	Prediction of patient-reported bowel quality of life (QOL) after dose-escalated radiation therapy (RT) for prostate cancer by rectal dosimetry.. <i>Journal of Clinical Oncology</i> , 2013, 31, 84-84.	1.6	0
32	Investigation of a novel irreversible pan-HER inhibitor combined with chemotherapy in bladder cancer models.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4545-4545.	1.6	0
33	A phase II trial of cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS5094-TPS5094.	1.6	0
34	Renal biopsy cell cycle proliferation (CCP) score to predict adverse surgical pathology in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 747-747.	1.6	0